|Bid||10.43 x 800|
|Ask||10.44 x 800|
|Day's range||9.69 - 11.19|
|52-week range||1.58 - 12.90|
|Beta (5Y monthly)||2.82|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.78|
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are rising sharply today following bullish commentary from a Wall Street analyst. The biopharmaceutical company's stock was up by 9.2% as of 1:11 p.m. EST, after jumping by as much as 10.6% earlier on Monday. Cowen analyst Ken Cacciatore initiated coverage on BioCryst stock with an outperform (buy) rating.
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results. BioCryst's shares were down by 8.4% as of 1:53 p.m. EST. BioCryst's total revenue for the fourth quarter ending Dec. 31 was roughly $4 million, down from the $39.7 million in revenue recorded during the year-ago period.
Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst fourth-quarter 2020 earnings call. Participating with me today are CEO Jon Stonehouse, CFO Anthony Doyle, Chief Medical Officer, Dr.